BeOne Medicines revenue surges 35% in Q1
BeOne Medicines Ltd, a listed global oncology biotech, reported a first-quarter revenue of $1.5 billion for 2026, up 35 percent year-on-year, driven by continued growth of its blood cancer drug, Brukinsa, and expansion into overseas markets. The US-listed Chinese biotech, also listed in Hong Kong and Shanghai, said Brukinsa generated $1.1 billion in global sales…









